Obesity drugs have reshaped Lilly's priorities

Of the top ten keywords mentioned in Eli Lilly's company filings this year, three relate to GLP-1RAs. Obesity alone has grown from 2 mentions in 2018 to 271 this year. (Company filings keyword mentions 2016-2023.)